Evidence map›Paper›PMID 31569420›Full record

ArticlePharmaceutics2019

Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent.

Seulgi Shin, Sungsu Lim, Ji Yeon Song, Dohee Kim, Min Jeong Choi, Changdev G Gadhe, A Young Park, Ae Nim Pae, Yun Kyung Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Seulgi ShinConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. seulgishin@kist.re.kr.
Sungsu LimConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. sungsulim@kist.re.kr.
Ji Yeon SongConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. aster1214@kist.re.kr.
Dohee KimConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. 213015@kist.re.kr.
Min Jeong ChoiConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. mjchoi@kist.re.kr.
Changdev G GadheConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. gadhe.changdev@gmail.com.
A Young ParkConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. 114054@kist.re.kr.
Ae Nim PaeConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. anpae@kist.re.kr.
Yun Kyung KimConvergence Research Center for Diagnosis, Treatment and Care System of Dementia, Brain science institute, Korea Institute of Science and Technology (KIST), Seoul 02791, Korea. yunkyungkim@kist.re.kr.ORCID 0000-0002-8682-120X
Convergence Research Center for Diagnosis Treatment and Care System of Dementia · KR

Funding

Korea Institute of Science and Technology 2V06480Ministry of Science, ICT and Future Planning 19-BR-03-02Ministry of Science, ICT and Future Planning CRC-15-04-KISTNational Research Foundation of Korea 2016M3C7A1913845National Research Foundation of Korea 2017R1A6A3A04012384
6 · The paper itself

Abstract

Glioblastoma drug development has been difficult due to the extremely low blood brain barrier (BBB) penetration of conventional anti-cancer agents. P-glycoprotein, an efflux membrane transporter, is responsible for the poor brain uptake of small and hydrophobic drug substances. To develop brain-penetrable anti-tumor agents, we designed colchicine derivatives containing an aryloxazole moiety, which is known to inhibit P-glycoprotein. Among those tested, an aryloxazole derivative named KIST-G1 showed the strongest anti-glioblastoma cell proliferation activity (IC

Indexed as

anti-glioblastoma agentaryloxazole derivativeP-glycoprotein inhibition

Identifiers

PMID31569420
PMCPMC6835410
OpenAlexW2976983696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.